Prytime Medical Devices, Inc. Announces Appointment of Donna Syracuse as Chief Commercialization Officer

Medical device veteran, Donna Syracuse, takes the lead for executing Prytime Medical’s commercialization for REBOA

SAN ANTONIO, Nov. 21, 2023 /PRNewswire-PRWeb/ — Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for noncompressible torso hemorrhage (NCTH), announced that Donna Syracuse, RN, has joined the company as Chief Commercialization Officer effective August 28, 2023.


Now that the pREBOA-PRO™ catheter has broken the 30-minute barrier, hospitals and providers want to see a programmatic approach implemented to achieve the best possible clinical results.

Donna Syracuse has over 25 years of Commercial and Nursing Leadership in critical care, nephrology, cardiology, peripheral vascular disease, and electrophysiology. Focused on clinical outcomes and evidence development, Donna was key in developing the HeRO® Graft market from launch to becoming Standard of Care for dialysis patients. She has built clinical programs around innovative technologies, building bridges and networks with and among thought leaders, physicians, clinicians, and administrators.

“I’m excited to join Prytime Medical at this point of its growth,” said Donna. She continued, “Now that the pREBOA-PRO™ catheter has broken the 30-minute barrier, hospitals and providers want to see a programmatic approach implemented to achieve the best possible clinical results. I look forward to building on Prytime’s Fanatical Clinical Support™ and Fanatical Program Support™ as we expand it further across North America.”

Most recently, Donna served in various Sales Leadership roles at Merit Medical, including Regional Vice President of Sales, and Vice President of the Peripheral Intervention Franchise. At Merit, her portfolio included products and therapies meeting a wide range of clinical needs including Renal Therapies, Intervention, Angiography, Cardiology, Drainage & Biopsy. She has a track record of success in building hospital-based clinical programs, driving revenue growth, and building commercial teams.

“Donna’s experience fits perfectly with Prytime’s strategic goal for building outcomes-driven REBOA programs,” said David Spencer, Prytime Medical CEO. “With her blend of clinical skills and consultative approach, Donna is best suited to help our customers realize the key benefits of True Partial REBOA™ using the pREBOA-PRO™ catheter: buying time, expanding treatment options, and reducing serious complications,” Spencer continued.

Prior to her career in medical devices, Donna was a nephrology and critical care nurse, receiving her degree from Queens Hospital Center School of Nursing.

Syracuse concluded, “I am very excited to join the Prytime team and support its mission that no one should bleed to death and the sooner you stop the bleeding, the better.”

About Prytime Medical Devices, Inc.

Prytime Medical™ Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control. The underlying intellectual property for REBOA was conceived based on lessons learned in war. Our latest innovations, the industry leading ER-REBOA™ PLUS, and the innovative pREBOA-PRO™ Partial REBOA Catheter, enable torso hemorrhage control with more controlled resuscitation in a much wider range of clinical scenarios. pREBOA-PRO™ is the first FDA-cleared REBOA catheter designed specifically for True Partial REBOA™. More information can be found at

Media Contact

Jeffrey Jung, Prytime Medical Devices, Inc, 210-544-1752,,


Cision View original content to download multimedia:

SOURCE Prytime Medical Devices, Inc

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. USA Newshour takes no editorial responsibility for the same.